

Correspondence

Intravenous immunoglobulin-mediated regulation of Notch ligands on human dendritic cells

To the Editor:

Massoud et al¹ demonstrated that intravenous immunoglobulin (IVIg) attenuates airway inflammation through induction of FoxP3⁺ regulatory T (Treg) cells.¹ They found that IVIg-primed dendritic cells (DCs) in ovalbumin-exposed mice exhibited decreased Jagged-1 and increased Delta-4 expression. Thus, the authors conclude that reduced T_H2 responses and induction of Treg cells by IVIg might involve modulation of Notch ligands on CD11c⁺ lung DCs.

As IVIg is also beneficial in patients involving predominant T_H1 responses, we explored whether data from mouse DCs under T_H2 pathologies could be translated to human DCs activated

under T_H1-promoting conditions. We studied the expression of not only Jagged-1 and Delta-4 but also all Notch ligands. Monocyte-derived DCs were stimulated with TLR4-agonist LPS for 24 hours. The effect of equimolar concentrations (0.15 mmol/L) of IVIg or irrelevant protein control human serum albumin² on the expression of all the Notch ligands was analyzed (see this article's Online Repository at www.jacionline.org).

We found that as compared with immature DCs, LPS stimulation lead to significant downregulation of Jagged-1 and IVIg did not modify the expression of Jagged-1 in LPS-stimulated DCs (Fig 1). Furthermore, LPS alone or with IVIg did not alter the expression of Delta-4 that was on par with unstimulated DCs. Similar results were also obtained with respect to Jagged-2a, Jagged-2b, Delta-1, and Delta-3. Although IVIg partially increased the expression of Jagged-2a, this increase was not significant




FIG 1. Expression pattern of Notch ligands on DCs. Real time RT-PCR analysis of various isoforms of Notch ligands in immature human monocyte-derived DCs, LPS-stimulated DCs, or DCs stimulated with LPS in combination with IVIg or HSA (n = 5). HSA, Human serum albumin.

and not specific as human serum albumin also imparted the same effect. Together our data indicated that IVIg does not modulate the expression of Notch ligands on activated DCs and hence modulation of T_H responses (and expansion of Treg cells) in humans following IVIg therapy could be independent of Notch ligands.

The disparities in the results obtained by Massoud et al and ours could be attributed to various factors. First, mouse and human Notch ligands show distinct differences in their ability to promote T-cell responses.³ While the stimulation of murine $CD4^+$ T cells with Jagged-1 lead to T_H2 responses,⁴ stimulation of human $CD4^+$ T cells by Jagged-1 promoted Treg cells.⁵ Thus, data of downregulated Jagged-1 expression on murine DCs by Massoud et al reflected downregulated T_H2 responses by IVIg in OVA-induced airway hyperresponsiveness model. As IVIg did not modify Jagged-1 expression on human DCs, our data suggest that Treg cell expansion by IVIg in human does not implicate Jagged-1. These results thus point toward distinct mechanisms of Treg-cell induction by IVIg in mouse and human depending on the type of pathologies in which IVIg is used.

Furthermore, DCs show enormous diversity and various subsets of DCs have been identified on the basis of tissue distribution, expression of innate receptors, response to stimuli, and functions. Thus, induction of T_H1 responses by $CD8^-$ splenic DCs by LPS was dependent on Delta-4 while those from $CD8^+$ DCs were dependent on IL-12.⁶ In human monocyte-derived DCs, LPS (from *Escherichia coli*) stimulation lead to large quantities of bioactive IL-12 (data not shown) and hence T_H1 polarization by these TLR4-stimulated DCs might be independent of Delta-4. Therefore, the role of Notch ligands in IVIg-mediated regulation of T-cell responses is also governed by the subset of DCs implicated in the process.

Jamma Trinath, MSc^{a,b}

Pushpa Hegde, MSc^{a,c}

Kithiganahalli N. Balaji, PhD^b

Srini V. Kaveri, DVM, PhD^{a,d,e,f}

Jagadeesh Bayry, DVM, PhD^{a,d,e,f}

From ^aUnité 872, Institut National de la Santé et de la Recherche Médicale, Paris, France; ^bthe Department of Microbiology and Cell Biology, Indian Institute of Science, Bangalore, India; ^cUniversité de Technologie de Compiègne, Compiègne,

France; ^dCentre de Recherche des Cordeliers, Equipe 16- Immunopathology and therapeutic immunointervention, Université Pierre et Marie Curie – Paris 6, Paris, France; ^eUniversité Paris Descartes, Paris, France; and ^fInternational Associated Laboratory IMPACT (Institut National de la Santé et de la Recherche Médicale, France - Indian council of Medical Research, India), National Institute of Immunohaematology, Mumbai, India. E-mail: jagadeesh.bayry@crc.jussieu.fr or srini.kaveri@crc.jussieu.fr.

This study was supported by Institut National de la Santé et de la Recherche Médicale, Université Pierre et Marie Curie, Université Paris Descartes (to S.V.K. and J.B.), Centre National de la Recherche Scientifique (to S.V.K.), European Community's Seventh Framework Programme (FP7/2007-2013, HEALTH-2010.2.4.5-2) under grant agreement HEALTH-No.: 260338 ALLFUN (to J.B.), Indian Institute of Science, Department of Biotechnology, Department of Science and Technology, Council for Scientific and Industrial Research (to K.N.B.), Coopération INSERM-ICMR-AO 2009/2010 (to K.N.B. and J.B.), and fellowships from INSERM-ICMR, Council for Scientific and Industrial Research (to J.T.).

Disclosure of potential conflict of interest: J. Trinath has received grants from INSERM-ICMR, Council for Scientific and Industrial Research, Government of India. S. V. Kaveri has received grants from Talecris Biotherapeutics. K. Balaji has received grants from the Department of Biotechnology, Department of Science and Technology, Council for Scientific and Industrial Research, Government of India (Coopération INSERM-ICMR-AO 2009/2010). J. Bayry has received grants from the European Community's Seventh Framework Programme (FP7/2007-2013, HEALTH-2010.2.4.5-2) under grant agreement HEALTH-No.: 260338 ALLFUN; Coopération INSERM-ICMR-AO 2009/2010; and Talecris Biotherapeutics. P. Hegde declares that she has no relevant conflicts of interest.

REFERENCES

1. Massoud AH, Guay J, Shalaby KH, Bjur E, Ablona A, Chan D, et al. Intravenous immunoglobulin attenuates airway inflammation through induction of forkhead box protein 3-positive regulatory T cells. *J Allergy Clin Immunol* 2012;129:1656-65.
2. Bayry J, Lacroix-Desmazes S, Carbonneil C, Misra N, Donkova V, Pashov A, et al. Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. *Blood* 2003;101:758-65.
3. Tsukumo S, Yasutomo K. Notch governing mature T cell differentiation. *J Immunol* 2004;173:7109-13.
4. Amsen D, Blander JM, Lee GR, Tanigaki K, Honjo T, Flavell RA. Instruction of distinct $CD4^+$ T helper cell fates by different notch ligands on antigen-presenting cells. *Cell* 2004;117:515-26.
5. Yvon ES, Vigouroux S, Rousseau RF, Biagi E, Amrolia P, Dotti G, et al. Overexpression of the Notch ligand, Jagged-1, induces alloantigen-specific human regulatory T cells. *Blood* 2003;102:3815-21.
6. Skokos D, Nussenzweig MC. $CD8^-$ DCs induce IL-12-independent $Th1$ differentiation through Delta 4 Notch-like ligand in response to bacterial LPS. *J Exp Med* 2007;204:1525-31.

<http://dx.doi.org/10.1016/j.jaci.2013.01.031>

METHODS

Generation of human monocyte-derived DCs

PBMCs were isolated from buffy coats of healthy blood donors obtained from Hôpital Hôtel Dieu, Etablissement Français du Sang, Paris, France. Ethical approval had been obtained for the use of such materials. CD14+ circulating monocytes were isolated from PBMCs by using CD14 magnetic beads (Miltenyi Biotec, Paris, France). The purity was more than 98%. Monocytes were cultured for 6 days in the presence of cytokines GM-CSF (1000 IU/10⁶ cells) and IL-4 (500 IU/10⁶ cells) (both from Miltenyi Biotec) to obtain DCs and were used for subsequent experiments.

Culture of DCs

DCs (0.5 × 10⁶/mL) were cultured with cytokines alone or cytokines plus LPS (100 ng/0.5 × 10⁶/mL, from *Escherichia coli*, Sigma-Aldrich, Lyon, France) for 48 hours. In additional conditions, following 1-hour stimulation of DCs with LPS, either IVIg (Sandoglobulin, CSL Behring AG, Bern, Switzerland) or human serum albumin (Laboratoire Française de Biotechnologies, Les Ulis, France) was added to cells at equimolar concentrations (0.15 mmol/L) and cultures were maintained for a total of 48 hours. IVIg was dialyzed before use and was tested negative for endotoxins.

Quantitative real-time RT-PCR

Total cellular RNA was isolated by using the RNA isolation kit (Invitrogen, Life Technologies, Saint Aubin, France) according to the manufacturers' instructions. A total of 0.5 µg of total RNA was reverse transcribed to obtain

the cDNA by using the miScript Reverse Transcription Kit (Qiagen, Courtaboeuf Cedex, France) following the instructions from the manufacturer.

Quantitative real-time RT-PCR was performed by using SYBR Green PCR mixture (KAPA Biosystems, Woburn, Mass) for quantification of the Notch ligands' expression at the level of mRNA.

The following PCR conditions were used:

Stage 1: 95°C initial denaturation

Stage 2: (95°C-30 seconds, 60°C-30 seconds, 72°C-40 seconds) for 40 cycles

Stage 3: 72°C-5 minutes final extension and data collection

Primer sequences used in the study were as follows:

Human Delta-1 forward: 5'TCCTGATGACCTCGCAACAGA 3'

Human Delta-1 reverse: 5'ACACACGAAGCGGTAGGAGT 3'

Human Delta-3 forward: 5'CACTCCCGGATGCACTCAAC 3'

Human Delta-3 reverse: 5'CCCGAGCGTAGATGGAAGGA 3'

Human Delta-4 forward: 5'TGGGTGAGAACTGGTTATTGGA 3'

Human Delta-4 reverse: 5'GTCATTGCGCTTCTTGACACAG 3'

Human Jagged-1 forward: 5'TCGGGTCAGTTCGAGTTGGA 3'

Human Jagged-1 reverse: 5'AGGCACACTTTGAAGTATGTGTC 3'

Human Jagged-2a forward: 5'AGCTGGACGCCAATGAGTG 3'

Human Jagged-2a reverse: 5'GTCGTTGACGTTGATATGGCA 3'

Human Jagged-2b forward: 5'TGGGCGGCAACTCCTTCTA 3'

Human Jagged-2b reverse: 5'GCCTCCACGATGAGGGTAAAG 3'

Human Glyceraldehyde-3 phosphate dehydrogenase forward:
5'ATGGGGAAGGTGAAGGTGCG 3'

Human Glyceraldehyde-3 phosphate dehydrogenase reverse:
5'GGGGTCATTGATGGCAACAATA 3'